232 related articles for article (PubMed ID: 22710833)
1. Loss of fused in sarcoma (FUS) promotes pathological Tau splicing.
Orozco D; Tahirovic S; Rentzsch K; Schwenk BM; Haass C; Edbauer D
EMBO Rep; 2012 Aug; 13(8):759-64. PubMed ID: 22710833
[TBL] [Abstract][Full Text] [Related]
2. Altered Tau Isoform Ratio Caused by Loss of FUS and SFPQ Function Leads to FTLD-like Phenotypes.
Ishigaki S; Fujioka Y; Okada Y; Riku Y; Udagawa T; Honda D; Yokoi S; Endo K; Ikenaka K; Takagi S; Iguchi Y; Sahara N; Takashima A; Okano H; Yoshida M; Warita H; Aoki M; Watanabe H; Okado H; Katsuno M; Sobue G
Cell Rep; 2017 Jan; 18(5):1118-1131. PubMed ID: 28147269
[TBL] [Abstract][Full Text] [Related]
3. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs.
Lagier-Tourenne C; Polymenidou M; Hutt KR; Vu AQ; Baughn M; Huelga SC; Clutario KM; Ling SC; Liang TY; Mazur C; Wancewicz E; Kim AS; Watt A; Freier S; Hicks GG; Donohue JP; Shiue L; Bennett CF; Ravits J; Cleveland DW; Yeo GW
Nat Neurosci; 2012 Nov; 15(11):1488-97. PubMed ID: 23023293
[TBL] [Abstract][Full Text] [Related]
4. FUS-mediated alternative splicing in the nervous system: consequences for ALS and FTLD.
Orozco D; Edbauer D
J Mol Med (Berl); 2013 Dec; 91(12):1343-54. PubMed ID: 23974990
[TBL] [Abstract][Full Text] [Related]
5. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
6. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
[TBL] [Abstract][Full Text] [Related]
7. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis.
Mackenzie IR; Neumann M
Brain Res; 2012 Jun; 1462():40-3. PubMed ID: 22261247
[TBL] [Abstract][Full Text] [Related]
8. A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10.
Yu Q; Guo J; Zhou J
J Neurochem; 2004 Jul; 90(1):164-72. PubMed ID: 15198676
[TBL] [Abstract][Full Text] [Related]
9. Importance of Functional Loss of FUS in FTLD/ALS.
Ishigaki S; Sobue G
Front Mol Biosci; 2018; 5():44. PubMed ID: 29774215
[TBL] [Abstract][Full Text] [Related]
10. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
[TBL] [Abstract][Full Text] [Related]
11. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
12. From transcriptomic to protein level changes in TDP-43 and FUS loss-of-function cell models.
Colombrita C; Onesto E; Buratti E; de la Grange P; Gumina V; Baralle FE; Silani V; Ratti A
Biochim Biophys Acta; 2015 Dec; 1849(12):1398-410. PubMed ID: 26514432
[TBL] [Abstract][Full Text] [Related]
13. Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain.
Rogelj B; Easton LE; Bogu GK; Stanton LW; Rot G; Curk T; Zupan B; Sugimoto Y; Modic M; Haberman N; Tollervey J; Fujii R; Takumi T; Shaw CE; Ule J
Sci Rep; 2012; 2():603. PubMed ID: 22934129
[TBL] [Abstract][Full Text] [Related]
14. [Aberrant Interaction Between FUS and SFPQ in Neurons in a Wide Range of FTLD Spectrum Diseases].
Ishigaki S
Brain Nerve; 2021 Sep; 73(9):1021-1028. PubMed ID: 34462374
[TBL] [Abstract][Full Text] [Related]
15. PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10.
Ray P; Kar A; Fushimi K; Havlioglu N; Chen X; Wu JY
J Mol Neurosci; 2011 Nov; 45(3):453-66. PubMed ID: 21881826
[TBL] [Abstract][Full Text] [Related]
16. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
A Armstrong R
Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
[TBL] [Abstract][Full Text] [Related]
17. ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation.
Zhou Y; Liu S; Liu G; Oztürk A; Hicks GG
PLoS Genet; 2013 Oct; 9(10):e1003895. PubMed ID: 24204307
[TBL] [Abstract][Full Text] [Related]
18. Tra2 beta, SF2/ASF and SRp30c modulate the function of an exonic splicing enhancer in exon 10 of tau pre-mRNA.
Kondo S; Yamamoto N; Murakami T; Okumura M; Mayeda A; Imaizumi K
Genes Cells; 2004 Feb; 9(2):121-30. PubMed ID: 15009090
[TBL] [Abstract][Full Text] [Related]
19. Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.
Suárez-Calvet M; Neumann M; Arzberger T; Abou-Ajram C; Funk E; Hartmann H; Edbauer D; Kremmer E; Göbl C; Resch M; Bourgeois B; Madl T; Reber S; Jutzi D; Ruepp MD; Mackenzie IR; Ansorge O; Dormann D; Haass C
Acta Neuropathol; 2016 Apr; 131(4):587-604. PubMed ID: 26895297
[TBL] [Abstract][Full Text] [Related]
20. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies.
Gu J; Chen F; Iqbal K; Gong CX; Wang X; Liu F
J Biol Chem; 2017 Jun; 292(25):10600-10612. PubMed ID: 28487370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
